InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 24.08B |
| Revenue (ttm) | 437.73M -34.5% |
| Net Income | -2.74B |
| EPS | -34.87 |
| Shares Out | 572.40M |
| PE Ratio | n/a |
| Forward PE | 187.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,056,900 |
| Open | 42.62 |
| Previous Close | 43.50 |
| Day's Range | 40.84 - 45.18 |
| 52-Week Range | 29.98 - 80.90 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 80.66 (+91.77%) |
| Earnings Date | Jul 3, 2026 |
About HKG:3696
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, softwar... [Read more]
Financial Performance
In 2025, HKG:3696's revenue was $56.24 million, a decrease of -34.48% compared to the previous year's $85.83 million. Losses were -$352.32 million, 1960.8% more than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 3696 stock is "Strong Buy." The 12-month stock price target is $80.66, which is an increase of 91.77% from the latest price.
News
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and pre...
AI shortens drug discovery to around 1 year in China, Insilico CEO says
Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said, giving it an edge over traditional Western pha...
Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine
Taiwan-based contract drugmaker Bora Pharmaceuticals will partner with Insilico Medicine on a collaboration aimed at improving efficiency, potentially valued at more than $2.5 billion if fully imple...
China Medical System to pay Insilico up to $177 million for nervous system work
Drugmaker China Medical System will pay Insilico Medicine up to about 1.2 billion yuan ($177 million) in milestone payments for a research and development programme in the central nervous system ...
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Hol...
Insilico Jumps On H1 Profit Forecast, Advances AI-Leveraged Rentosertib To Phase III Trial In IPF
(RTTNews) - InSilico Medicine Cayman TopCo Ltd. (3696.HK), an AI-driven clinical-stage biotechnology company, reported improved first-half 2026 earnings expectations, driven by revenue growth from out...
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today deliv...
Insilico Medicine Announces Strategic AI Drug Discovery Collaboration With Takeda
(RTTNews) - Insilico Medicine (3696.HK), a clinical-stage company specializing in generative AI for drug discovery, has entered into a strategic collaboration with Takeda Pharmaceutical Company Ltd. (...
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader...
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
InSilico Is on a Mission: Be No. 1 in China, Create ‘God Drug' With AI
The pharma company, the first to use generative AI to develop a drug that reached clinical trials, is betting longevity treatments will fuel its next phase of growth.